In a time study we compared the analytical and clinical performance of the Tandem Icon QSR CK-MB enzyme-immunoassay (Hybritech) (creatine kinase-MB) and a creatine kinase-MB immunoinhibition method (Boehringer Mannheim GmbH) (creatine kinase-B). Two hundred and ninety-nine serum samples from 38 patients suspected of acute myocardial infarction were collected at regular intervals during 48 hours. Twenty-nine patients were diagnosed as having acute myocardial infarction, of whom 19 recieved thrombolytic therapy. Although highly correlated, the large scatter around the regression line at low values indicated a different clinical performance of the two methods. We evaluated and compared test performance at different decision levels by means of frequency distributions and predictive values of positive and negative results. For early diagnosis of acute myocardial infarction (4 hours after onset of pain) the Hybritech creatine kinase-MB method gives acceptable predictive values. In thrombolytic treated acute myocardial infarction patients, the peak creatine kinase-MB and creatine kinase-B concentrations were reached after 13
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low (mean 5 μg/l); N = 10) patient serum pool were 6% and 15% respectively. Creatine kinase-B betweenassay CV was 5% (mean 40 U/l, N = 12) and 25% (mean 10 U/l, N = 38).
Materials and Methods

Analytical methods
Creatine kinase-MB mass concentration was assayed with the Tandem Icon QSR CK-MB quantitative test (Hybritech Inc., San Diego, California) as specified by the manufacturer. This assay is specific for creatine kinase-MB isoenzyme and uses two monoclonal antibodies, one binding to the M-subunit and the other to the B-subunit of the creatine kinase-MB molecule. Each test cylinder contains test zones for low and high calibrator and for duplicate sample. Results were measured on a reflectometer (Hybritech Icon Reader). The detection limit was 2 μg/l (manufacturer's specifications).
Creatine kinase-MB catalytic activity (creatine kinase-B) was assayed with creatine kinase-MB (N-acetyl cysteine (NAQactivated) reagents (Boehringer Mannheim GmbH Diagnostica, Mannheim, Germany) at 37 °C (our routine laboratory method). After selective inhibition of the creatine kinase-M subunit, the residual creatine kinase-B activity was measured.
Results were corrected for adenylate kinase activity. This assay also measures creatine kinase-BB and macro creatine kinase (7) when present. The method was adapted to the RA 1000 autoanalyser (Technicon Instruments Corporation, Tarrytown, USA).
Patients
We assayed 299 blood samples from 38 patients. Blood was collected from the antecubital vein at approximately 0, 3, 6, 9, 12, 18, 24, 36 and 48 hours after admission. For some patients the sample series were not complete. The samples were centrifuged and serum was stored at 4-8 °C for measurement of creatine kinase-B within 24 hours in our in-house routine assay, and at -70 °C for measurement of creatine kinase-MB within 2 months.
All samples assayed were from patients admitted to the coronary care unit with acute ischaemic syndrome and included in the Myocardioscintigraphy in Acute Ischaemic Syndrome project. The diagnosis of acute myocardial infarction was established on the basis of clinical history, daily 12-lead electrocardiogram and enzyme results, not including creatine kinase-B and creatine kinase-MB. Twenty-nine patients were diagnosed as having acute myocardial infarction, and 19 of these recieved thrombolytic therapy (streptokinase 1.5 χ ΙΟ 6 IU).
The patients were admitted 3/4 hours (mean) (range 2!/2 to 14 hours) after the onset of pain. In 26 of the patients the first blood sample was collected within 4 hours after onset of pain and in 9 patients the first sample was collected so close to 4 hours that extrapolation from the time curve could be applied.
Analytical correlation
The correlation between creatine kinase-MB mass concentration (y) and creatine kinase-MB enzyme catalytic activity (x) is shown in figure 1 . 
Statistical method
Demings correlation test was used for comparison of creatine kinase-B and creatine kinase-MB results (10).
Results
Analytical imprecision
Creatine kinase-MB between-assay coefficient of variation (CV) for a high (mean 21 μg/l; Ν = 10) and a
Frequency distribution
Histograms (11) for test results were drawn for both tests ( fig. 2a and 2b) . •20 hour values were similar to the peak values and there-. 15 fore not shown. tine kinase-MB ( fig. 3a and 3b ) and creatine kinase-B ( fig. 4a and 4b ), using the onset of pain as time zero.
Using the decision limit 9 μg/l for creatine kinase-MB and 20 U/l for creatine kinase-B we found that in the patients receiving thrombolytic therapy, the duration of positive creatine kinase-MB was 48.3 h (16 -72) compared with 43.0 h (23 -65) for creatine kinase-B (NS). Time to peak was 13.0 h (2.5-26.0) for creatine kinase-MB, compared with 13.6 h (3.0-26.0) for creatine kinase-B (NS). In the patients who did not receive thrombolytic therapy, the duration of positive test results was 51.6 h (42 -68) for creatine kinase-MB and 31.5 h (17-46) for creatine kinase-B (p < 0.01). Time to peak was 19.8 h (10-45) for creatine kinase-MB, compared with 17.8 h (10-42) for creatine kinase-B (NS).
Although both methods gave different mean values for the time to peak in patients with and without thrombolytic treatment, this was not statistically significant, and probably the result of using a small number of patients.
Discussion
Our objectives were to investigate the conceivable advantage in using one of the new specific tests for creatine kinase-MB, especially in the early diagnosis of acute myocardial infarction, which may support the use of thrombolytic therapy of acute myocardial infarction (7).
As observed, the creatine kinase-MB mass concentration and the creatine kinase-MB enzyme activity correlated well for elevated enzyme concentrations, in agreement with other studies (12, 13) . We did not multiply our enzyme activity results by a factor 2 (to compensate for the blocking of the M-subunit), which explains the lower specific activity in our study compared with others. However, at low values (< 50 U/l) the correlation was poor (note the large scatter at low values in figure 1 (insert) ), due to the high imprecision of both tests in this range, especially the creatine kinase-B.
The frequency distribution histograms showed that the creatine kinase-MB mass concentration assay could be used in early diagnosis (4 hours after onset of pain) with a PVpos greater than 0.9, combined with a PVneg greater than 0.75, which was never obtained for the creatine kinase-MB activity method. At the enzyme peak concentration, comparable predictive values were obtained for both methods. At the peak concentration, acceptable clinical performance was obtained for the creatine kinase-MB activity method, using the decision limits of 12 and 20 U/l. At 8 hours after the onset of pain the performance characteristics for both methods were very similar to those at enzyme peak concentrations (not shown). Based on the decision limits of 9 μg/l for creatine kinase-MB and 20 U/l for creatine kinase-B, the duration time for the positive test in patients who not receiving thrombolytic therapy was significantly longer for creatine kinase-MB than for creatine kinase-B. In patients receiving thrombolytic therapy, the duration time for both methods was not significantly different.
In agreement with other studies (14, 15) , both methods showed a difference in time to peak between thrombolytic treated patients and non-treated patients; but in our study this difference was not significant (p < 0.1 for creatine kinase-MB and p < 0.25 for creatine kinase-B), probably due to the small number of patients.
We conclude that both methods provide sufficient predictive values for both positive and negative diagnosis of acute myocardial infarction at eight hours after the onset of pain. The creatine kinase-MB also gives acceptable predictive values for early diagnosis (4 hours after onset of pain), which is claimed to be crucial for successful thrombolytic therapy (1) and may therefore be of value to the clinician as a diagnostic support in the treatment of acute myocardial infarction. The appropriate decision limits should be chosen from the frequency distribution histograms, with due consideration for the prevalence and the costs of false results.
